CYTOMEGALOVIRUS (CMV)
Clinical trials for CYTOMEGALOVIRUS (CMV) explained in plain language.
Never miss a new study
Get alerted when new CYTOMEGALOVIRUS (CMV) trials appear
Sign up with your email to follow new studies for CYTOMEGALOVIRUS (CMV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope against viral threat in modern cancer therapy
Disease control Recruiting nowThis study tests the drug maribavir in 20 adults with multiple myeloma or lymphoma who develop a cytomegalovirus (CMV) infection while receiving bispecific antibody treatment. The goal is to see if maribavir can safely lower CMV levels in the blood. Participants will take maribav…
Matched conditions: CYTOMEGALOVIRUS (CMV)
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
New hope for transplant patients with Drug-Resistant CMV
Disease control Recruiting nowThis study tests a drug called maribavir in Chinese adults who have had a stem cell or organ transplant and have a CMV infection that no longer responds to standard treatments. The main goal is to see if maribavir is safe and well-tolerated, and also how well it clears the virus.…
Matched conditions: CYTOMEGALOVIRUS (CMV)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
New study tracks Real-World use of maribavir for Post-Transplant CMV
Disease control Recruiting nowThis study looks at how maribavir is used and how well it works for adults who get a common virus called CMV after an organ or stem cell transplant. Researchers will follow 75 people in Belgium for up to 2 years, collecting data from regular doctor visits. The goal is to see if t…
Matched conditions: CYTOMEGALOVIRUS (CMV)
Sponsor: Takeda • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for transplant patients with stubborn CMV infection
Disease control Recruiting nowThis study in Japan tracks 250 organ or stem cell transplant patients whose CMV infection hasn't cleared with standard treatments. They will take Maribavir tablets as part of their normal care, and doctors will watch for side effects and check if the virus clears from the blood o…
Matched conditions: CYTOMEGALOVIRUS (CMV)
Sponsor: Takeda • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New drug LIVTENCITY tracked in Real-World use for transplant patients with CMV
Disease control Recruiting nowThis study monitors how safe and effective the drug LIVTENCITY (maribavir) is for adults who develop CMV infection after an organ transplant. About 168 participants in South Korea will be followed for 20 weeks during routine care. The goal is to see how well the drug works in eve…
Matched conditions: CYTOMEGALOVIRUS (CMV)
Sponsor: Takeda • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
New study aims to stop a common virus threat after kidney transplant
Prevention Recruiting nowThis study tests two different approaches to prevent cytomegalovirus (CMV) disease in adults who have received a kidney from a CMV-positive donor but are themselves CMV-negative. One group will take daily antiviral medication for 200 days, while the other will have weekly blood t…
Matched conditions: CYTOMEGALOVIRUS (CMV)
Phase: PHASE3 • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated May 17, 2026 05:34 UTC
-
Researchers check drug safety for transplant patients with kidney problems
Knowledge-focused Recruiting nowThis study looks at medical records of 10 adults who had a transplant and later got a CMV infection that was hard to treat, along with severe kidney disease or kidney failure (including those on dialysis). The goal is to see if the drug maribavir caused any side effects. No new t…
Matched conditions: CYTOMEGALOVIRUS (CMV)
Sponsor: Takeda • Aim: Knowledge-focused
Last updated May 17, 2026 05:29 UTC